Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel(Chinese University of Hong Kong), Rury R. Holman(Chinese University of Hong Kong), Rishi Patel(University of Oxford), John B. Buse(University of North Carolina at Chapel Hill), Robert J. Mentz, Neil R Poulter(University of Leicester), Stephanie M. Gustavson(Chinese University of Hong Kong), Aldo P. Maggioni, Neha J. Pagidipati(Alnylam Pharmaceuticals (United States)), Bernard Zinman(Lunenfeld-Tanenbaum Research Institute), Juliana C.N. Chan(Chinese University of Hong Kong), Yuliya Lokhnygina(Clinical Research Institute), Nayyar Iqbal(Chinese University of Hong Kong), Peter Merrill(Duke University), Ambady Ramachandran(India Diabetes Research Foundation), Peter Öhman(Chinese University of Hong Kong), Adrian F. Hernandez(Duke University)
Cited by 591
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
|New England Journal of Medicine|2008|7.4k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k